Search results for "anticoagulant drugs"

showing 4 items of 4 documents

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards

2018

no abstract available

MaleAdministration Oral030204 cardiovascular system & hematologyBody Mass IndexOral anticoagulant drug0302 clinical medicineElderlyDrug PrescriptionOlder patientsRetrospective Studie80 and overMedicine030212 general & internal medicineStrokeRandomized Controlled Trials as TopicAged 80 and overAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Internal MedicineAtrial fibrillationStrokeObservational Studies as TopicAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate Internal MedicineAdministrationOral anticoagulantFemaleHumanOralmedicine.medical_specialtyOral anticoagulant drugsSocio-culturaleDrug Prescriptions03 medical and health sciencesInternal medicineInternal MedicineHumansPrescription rateAgedRetrospective Studiesbusiness.industrySettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studymedicine.diseaseAtrial fibrillationAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Administration Oral; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Observational Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke; Internal MedicineObservational Studies as TopicbusinessBody mass indexAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate
researchProduct

Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study

2021

Background: The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. Material and methods: From all patients in LIPIDOGRAM2015 Study (n = 13,724), 268 subjects had a history of ischaemic stroke and were included. Results: 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were a…

Oral anticoagulant drugsmedicine.medical_specialtyRMArticleLifestyle modificationOral antiplatelet drugsInternal medicineIschaemic strokemedicineMyocardial infarctioncardiovascular diseasesSecondary stroke preventionStrokePrimary health careoral anticoagulant drugssecondary stroke preventionbusiness.industryRAtrial fibrillationoral antiplatelet drugsGeneral Medicinemedicine.diseaseR1Coronary heart diseaseprimary health careStroke preventionConcomitantMedicinebusiness
researchProduct

Dental treatment of patients with coagulation factor alterations: An update

2007

Hemostasia is a defense mechanism that protects vascular integrity, avoids blood loss, and maintains blood fluidity throughout the circulatory system. The biochemical processes leading to blood clot formation are complex, and alterations can appear at any point within the chain of events. While a range of alterations can affect the coagulation factors, some are more common than others in the general population, including congenital (hemophilia A and B, Von Willebrand’s disease) and acquired disorders (anticoagulant drugs). Such diseases require special consideration in the context of dental treatment, and therefore must be known to dental professionals. Interconsultation with the hematologi…

prevencióninterconsultaanticoagulant drugscoagulation factors:CIENCIAS MÉDICAS [UNESCO]hemofiliapreventionVon Willebrand’s diseasehemophiliaUNESCO::CIENCIAS MÉDICASfactores de coagulaciónHemostasiaenfermedad de von WillebrandVon Willebrand’s diseasefármacos anticoagulantesaccidentes hemorrágicosinterconsultationbleeding accidents
researchProduct